Vanishing white matter disease
Oct. 30, 2024
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Globoid cell leukodystrophy …
- Updated 05.14.2024
- Released 12.28.1993
- Expires For CME 05.14.2027
Globoid cell leukodystrophy
Introduction
Overview
Globoid cell leukodystrophy, or Krabbe disease, is an autosomal recessive, rapidly progressive fatal disease when it occurs in infancy. The disease usually begins between the ages of 3 and 6 months with ambiguous symptoms, such as irritability or hypersensitivity to external stimuli, but soon progresses to severe mental and motor decline. Patients are initially hypertonic with hyperactive reflexes, but they later become flaccid and hypotonic. Blindness and deafness are common. Patients with late-onset forms, including adult-onset, may present with blindness, spastic paraparesis, and dementia. Saposin A deficiency is a rare cause of Krabbe disease. Brain MRI has characteristic features that depend on the age of onset of the disease (infantile, juvenile, or adult). Optic nerve and cauda equina enlargement and enhancement are common, as is midbrain atrophy. The presence of peripheral nerve enlargement detected by ultrasound strongly supports the diagnostic possibility of Krabbe disease (58). Newborn screening and presymptomatic hematopoietic stem cell transplantation have not yielded clear benefits.
Key points
|
• Globoid cell leukodystrophy may occur at any age, but the infantile type is the most common. | |
|
• Typical MRI changes that vary according to each phenotype suggest the diagnosis. | |
|
• The adult-onset type is the most prevalent in certain populations, such as Japan. | |
|
• Hematopoietic stem cell transplantation in presymptomatic infants only mitigates the disease and is not the optimal therapy it was once hoped to be. | |
|
• Measuring psychosine, a major offending metabolite in Krabbe disease, in dried blood spots helps in diagnosis and differentiation of infantile from later onset variants and in monitoring of disease progression and response to treatment. |
Historical note and terminology
Globoid cell leukodystrophy, or Krabbe disease, was described in 1916. Danish neurologist Knud Haraldsen Krabbe (1885-1961) reported the clinical and neuropathologic description of five cases that appeared to represent a new disease entity (54).
Previous neuropathologic studies by American neuropathologist William Norton Bullard (1853-1931) and American neuropsychiatrist and neuropathologist Elmer Ernest Southard (1876-1920), working at Boston City Hospital in 1906, and German pathologist Rudolf Beneke (1861-1946) in 1908, however, had already described the "diffuse gliosis" of brain that was later characterized as "diffuse brain-sclerosis" in Krabbe patients (11; 08).
In 1924, English neurologist James Stansfield Collier (1870-1935) and Scottish neuropathologist Joseph Godwin Greenfield (1885-1958) used the term "globoid cells" to describe the phagocytic cells that appeared to be unique to this disorder (21). German neuropathologist Julius Hallervorden (1882-1965), a former member of the Nazi Party (ie, the National Socialist German Workers' Party) who had knowingly performed much of his research on the brains of executed prisoners and participated in the action T4 euthanasia program, suggested that these globoid cells may contain kerasin or cerebroside (36).
Biochemical and histochemical studies confirmed the presence of cerebroside in globoid cells (09; 05), and galactocerebroside was the only glycolipid that could produce globoid cells when injected into the central nervous system of experimental animals (03). Analytical biochemical studies of total brain lipids did not show an increase in galactosylcerebroside in this disease, but rather a lowering of total cerebroside and sulfatide and a reduced sulfatide-to-cerebroside ratio (95). Only a fraction of brain lipids enriched in the specialized globoid cells showed increased galactosylceramide (05). In 1970, Malone reported a deficiency of leukocyte galactosylceramide beta-galactosidase in a Krabbe disease patient (68); this was confirmed by Suzuki and Suzuki, who demonstrated the enzyme deficiency in the brain, liver, and spleen of three patients with Krabbe disease (93). Psychosine, a related glycolipid, was suggested to be the toxic metabolite responsible for the pathogenesis of this disorder (71; 92). The gene for the galactosylceramidase (GALC) enzyme has been mapped to chromosome 14 (113), and the cDNA has been cloned by Chen and colleagues (17).
Clinical manifestations
Presentation and course
Initial clinical reports of Krabbe disease described the classic early infantile presentation (54). The early infantile presentation, which accounts for over 70% of globoid cell leukodystrophy, begins before 6 months of age in most cases, and in 25% of cases, prior to 3 months of age (66; 103; 56).
Delayed motor milestones and subsequent regression of previously acquired milestones are typical.
Gross and fine motor development and disease course in early-infantile Krabbe disease
Categories are represented by symbols. The symbols for each category are linked together for better identification. (Source: Krieg SI, Krägeloh-Mann I, Groeschel S, et al. Natural history of Krabbe disease: a nationwide study i...
Patients commonly develop spasticity early in the disease course, followed by feeding difficulties requiring placement of a gastrostomy tube, loss of fixation, and epileptic seizures late in the course.
Many acquire the ability to walk, albeit with reduced quality of performance, but then there is progressive loss of ambulation progressing to no ambulation but with some retained ability to control movements of the head; the decline from ambulation with reduced quality to no ambulation but some retained head control occurs over a wide span of time from several months to up to 10 years later.
|
• Stage 1: Sensitivity to noise and light, periodic fever without infection, stagnation and then regression of development, and increased tone with normal deep tendon reflexes. | |
|
• Stage 2: Permanent opisthotonos, tonic flexion of arms and extension of legs, loss of nearly all previously acquired skills, myoclonic jerks, seizures, optic atrophy, and blindness. | |
|
• Stage 3: Immobile, decerebrate, hypotonic, and unable to feed. |
However, the disease progresses in a continuum, as was demonstrated in a prospective study of a large cohort of children presenting at 0 to 5 months of age (07). Children may rarely present in the neonatal period, but this is an uncommon occurrence (66); a prenatal onset was first suggested when a 5-month-old fetus was noted to have the characteristic neuropathologic findings (26). Cerebrospinal fluid protein is usually elevated (66).
Much less common is a late-infantile variant for which the age of onset is between 19 months and 4 years (63). Affected children have normal intelligence or are only moderately retarded during the first years but then gradually develop ataxia, weakness, spasticity, and later dysarthria. Cases with onset after 12 months have less peripheral nerve involvement and slower disease progression (06). Visual loss with the early onset of optic atrophy, mental regression, occasional seizures, deafness, and normal peripheral nerves are the characteristic findings. A slowly progressive spinocerebellar degeneration associated with peripheral neuropathy, but without visual loss or dementia, has been reported (99). As in other forms of globoid cell leukodystrophy, CSF protein is usually, but not always, elevated (63). Peripheral neuropathy may be of the demyelinating type or predominantly axonal (67). These can very rarely have relatively high residual galactocerebrosidase activity (55).
Late-onset variants of globoid cell leukodystrophy have been somewhat arbitrarily defined as juvenile-onset (beginning between 4 and 19 years of age) and adult-onset (20 years of age and older) (103; 28; 60; 30; 39; 75; 82). These patients usually have optic nerve pallor, pes cavus, slowly progressive spastic tetraplegia, and sensory-motor demyelinating polyneuropathy with preserved mental function in approximately one half of the affected individuals; cranial CT shows hypodensity in the parieto-occipital white matter, and brain MRI shows symmetric, parieto-occipital predominant, periventricular abnormality with high signal in the pyramidal tracts, eventually with involvement of the splenium of the corpus callosum and optic radiations (86; 23). A detailed description of 20 patients with adult-onset Krabbe disease showed that the corticospinal tract was always affected, but other areas in the brain were also often involved, whereas the genu of the corpus callosum was always normal (22). The pyramidal tracts can be involved in isolation in middle-aged patients (100). The adult-onset form is the most common phenotype in Japan (42). CSF protein is frequently not increased. The lifespan of individuals with the late-onset variant may vary, but survival for over 24 years has been reported (04). Interestingly, 82% of Chinese patients have late-onset Krabbe disease (112).
Prognosis and complications
Untreated children with the early infantile form of globoid cell leukodystrophy rarely live past 2 years of age. The late-infantile variant may have a much more prolonged course, with death usually occurring 1 year to 6 years after onset. In one report, however, the patient was not diagnosed until 34 years of age despite symptoms beginning in the late infantile period (99). In juvenile-onset and adult-onset patients, the disease will frequently have a much more protracted course (60).
Clinical vignette
A 4-month-old child was brought in for irritability that manifested as a high-pitched cry and poor feeding. The child had prior unexplained fevers associated with episodes of extreme irritability. On examination, the child was hypotonic and kept the hands continuously fisted. Muscle stretch reflexes were reduced, but Babinski sign was present. No optic atrophy was evident. An EEG was only minimally abnormal, with occasional paroxysmal beta waves noted over the vertex. CT scan demonstrated increased attenuation in the thalamus and basal ganglia but decreased attenuation in the white matter. Laboratory studies included serum amino acids, urine organic acids, viral titers for congenital infections, serum lactate, and pyruvate, all of which were normal. CSF examination demonstrated normal cell count, lactate, and pyruvate, but protein was increased to 158 mg/dL. A leukocyte galactosylceramidase level was 0.03 nmol galactose/mg protein per hour with a control of 2.3, confirming the diagnosis of Krabbe disease. The child died of a respiratory infection at 15 months of age.
Biological basis
Etiology and pathogenesis
Globoid cell leukodystrophy is caused by a deficiency of the enzyme galactosylceramidase.
Neuropathology. Krabbe disease is categorized as a leukodystrophy because most neuropathologic changes are noted in the white matter of the brain and in the peripheral nerves. The typical neuropathologic findings in these patients include severe loss of oligodendroglia, myelin, and axons, as well as dense astrocytic proliferation and the presence of "globoid cells."
Mulinucleated macrophages with PAS-positive inclusions ("globoid cells") within astrocytic gliosis and loss of myelinated fibers in Krabbe disease leu...
(Photomicrograph by Jensflorian on July 14, 2011. Creative Commons Attribution-Share Alike 3.0 Unported License, creativecommons.org/licenses/by-sa/3.0/deed.en.)
In the murine model of Krabbe disease (a twitcher mouse), the oligodendrocyte loss is caused by an apoptotic depletion (96). Loss of myelin can also be seen in peripheral nerves; however, typical globoid cells are frequently not observed (69). Although the identification is somewhat controversial, these characteristic globoid cells appear to be specialized macrophages originating from mesoderm (03).
Ultrastructurally, globoid cells may be mononuclear or multinuclear; the latter contain two types of membrane-bound tubules. These tubules are either slender twisted tubules similar to those observed in Gaucher disease or a larger straight or arched variety (109).
Genetics. Krabbe disease is inherited as an autosomal recessive trait.
The gene for galactosylceramidase (GALC) was mapped to chromosome 14 (14q.31) by linkage analysis (113) and confirmed by in situ hybridization using a portion of the human cDNA for this gene (14). Following the difficult purification of the galactosylceramidase enzyme from human urine (18), the cDNA encoding GALC was cloned (17). Sodium dodecylsulfate-polyacrylamide gel electrophoresis of fractions containing the purified enzyme showed bands corresponding to 80 kD, between 50 and 52 kD, and 30 kD, all of which have a similar N-terminal amino acid sequence. This sequence similarity suggested that the 50 kD and 30 kD species are derived from the 80 kD precursor species (17; 18). The cDNA is 3.8 kb in length and contains a 2007 bp open reading frame that codes for 669 amino acids representing an unglycosylated protein with a molecular weight of 72,781 (18). This weight is consistent with the glycosylated 80 kD precursor form identified (17). Confirmation of the deduced amino acid sequence for the cDNA occurred following the purification of the enzyme from human leukocytes and the subsequent cloning using the polymerase chain reaction method (81). The entire gene structure and organization has been determined to consist of nearly 60 kb with 17 exons and 16 introns (64). The promoter region, located at the 149 to 112 nucleotide region from the initiation codon, contains three galactocerebroside-box-like sequences and one YY1 binding site (80). A common polymorphism in the human GALC gene occurs at nucleotide position 1637, where either a T or C may be present. The enzyme derived from the 1637T allele has 1.5- to 2-fold more activity than the enzyme derived from 1637C, which explains the wide range of human GALC gene activity in the general population (24).
Molecular analyses demonstrated at least 73 mutations, including base transitions, polymorphisms, and deletions that are associated with Krabbe disease Human Gene Mutation Database GALC web page. In infantile Krabbe disease patients of Northern European ancestry, approximately 40% to 50% have a mutant allele that has a 30 kb deletion beginning in intron 10 and extending past the 3’ end of the gene (50). In addition to the deletion on this allele, an invariable C →T transition at position 502 exists, which is a polymorphism seen in only about 4% of the population. Improved detection of mutations using comparative genomic hybridization (CGH) to analyze the GALC gene has been described (97). Most of the mutations causing infantile-onset disease are located on the region coding for the 30 kD subunit of the enzyme, suggesting that this subunit is critical for the normal enzyme function (103). Adult-onset cases may also have the 502/del mutation on one allele, but many other mutations have been identified, which appear to occur predominantly in the region coding for the 50 kD subunit (29; 84; 24).
Biochemistry of Krabbe disease. Experimentally, the only glycolipid that could produce globoid cells when injected into the cerebral cortex was galactosylceramide (03). Initial biochemical studies of brains from patients with Krabbe disease demonstrated the accumulation of the glycolipid, galactosylceramide, only within a fraction of brain that was enriched in globoid cells (05). However, total glycolipid and sulfatide levels in white matter from these brains were reduced (05). The association between galactosylceramide and Krabbe disease was confirmed when the enzyme that degrades galactosylceramide, galactosylceramidase, was found to be deficient in the leukocytes, brain, liver, and spleen of Krabbe disease patients (68; 93). Elevated expression of matrix metalloproteinase (MMP-3) and tenascin-C may mediate the production of globoid cells in Krabbe disease (46; 20).
Galactosylceramidase hydrolyses not only galactosylceramide, but also other glycolipids containing a terminal beta-galactose group, such as lactosylceramide, monogalactosyl diglyceride, and galactosylsphingosine (psychosine) (71; 104; 102). To properly function, the galactosylceramidase enzyme requires a sphingolipid activator protein, saposin A or saposin C, which helps solubilize the protein-lipid complex (37). Saposin A and saposin C also activate the degradation of galactosylsphingosine (37). A very rare deficiency of saposin A leads to a phenotype identical to that of early-infantile Krabbe disease caused by GALC enzyme deficiency (13). A second lysosomal enzyme, GM1 ganglioside beta-galactosidase, hydrolyzes GM1 ganglioside, and its deficiency is associated with the storage disease GM1 gangliosidosis. Different, but overlapping substrate specificity exists for these two beta-galactosidase enzymes; under certain conditions GM1 ganglioside beta-galactosidase can hydrolyze galactosylceramide, but not psychosine (52).
Although galactosylceramide does not accumulate in the white matter of affected individuals except in the specialized globoid cells (05), psychosine is increased in the brains of patients with Krabbe disease (92). Psychosine has been demonstrated to cause cell death and injury to oligodendrocytes in culture that can be ameliorated by the presence of compounds that activate protein kinase C, activate galactosylceramidase, or bind to psychosine (19). Researchers found that psychosine localizes to detergent-resistant membrane microdomains (lipid rafts), perturbs natural and artificial membrane integrity, and inhibits protein kinase C translocation to the plasma membrane (38). These data strongly suggest that a significant component of psychosine toxicity is achieved through membrane perturbation rather than through protein-psychosine interactions (38). In the twitcher mouse, psychosine seems to accumulate in lipid rafts causing a maldistribution of cholesterol and specific proteins, which leads to a dysfunction of protein kinase C (105). Psychosine also inhibited fast axonal transport through the activation of axonal PP1 and GSK3beta in the axon (15). Abnormal levels of activated GSK3beta and abnormally phosphorylated kinesin light chains were found in nerve samples from a mouse model of Krabbe disease (15). It has been proposed that because of the overlapping substrate specificity of the beta-galactosidase enzymes, only psychosine and not galactosylceramide accumulates in the brains of Krabbe disease patients (92). Toxic psychosine or galactosylsphingosine accumulation may be responsible for the apoptotic depletion of oligodendroglial cells and the abnormal myelination in this disease. Further confirmation of the role of psychosine in Krabbe disease has been obtained by deleting the activity of acid ceramidase in the Twitcher mouse (59). The combination of a single gene defect prevented psychosine elevation in the Twitcher mouse and a marked improvement in its phenotype (59). Psychosine is generated catabolically through the deacylation of galactosylceramide by acid ceramidase. Although bone marrow transplantation normalizes the level of psychosine in the brain, transplanted mice still end up succumbing to the disease (65).
The spectrum of disorders of the lysosomal degradation of glycosphingolipids. Ceramide is synthesized in vivo in multiple steps, by de novo synthesis, hydrolysis of sphingomyelin, or the salvage pathway from sphingosine.
Ceramide, in turn, can be metabolized to various other molecules needed for cellular metabolism, including gangliosides, sphingomyelin, and sulfatide.
The various sphingolipids are closely related from a structural perspective.
The lysosomal degradation of glycosphingolipids proceeds through multiple enzymatic steps, with specific recognized diseases corresponding to abnormal enzymatic activity at multiple sites in the metabolic pathways (GM1 gangliosidosis, Tay-Sachs disease, Sandhoff disease, sialidosis, Fabry disease, Gaucher disease, metachromatic leukodystrophy, Krabbe disease, and Farber disease.
-
Lysosomal degradation of glycosphingolipids with responsible gene products and diseases connected to defects
Abbreviations: ASA, Arylsulfatase A; ASAH1, acid ceramidase; GALC, β-galactosylceramidase; GBA, β-glucocerebrosidase; GLA, α-galactosidase A; GLB1, β-galactosidase; HEXA, β-hexosaminidase A; HEXB, β-hexosaminidase B; NEU3/4, ne...
-
Lysosomal sphingolipid catabolism and enzyme deficiencies causing storage diseases
A schematic of the various sphingolipid metabolic pathways shows the enzymes whose deficiency leads to several diseases. Note that each enzyme is assisted by one or more saposins (Saps): (1) GM2A assists both β-gal and β-hexosa...
As noted above, the enzymatic block in Krabbe disease is in the conversion of galactosylceramide (GalCer) to ceramide through the action of β-galactosylceramidase, which is the gene product of GALC.
Epidemiology
Globoid cell leukodystrophy is inherited as an autosomal recessive trait; therefore, it affects males and females equally and appears to be panethnic.
The prevalence of Krabbe disease in the general population is not known, but a report from Sweden estimated the prevalence to be 1.9 per 100,000 population (35), whereas in Japan the estimated prevalence was between 0.5 to 1 per 100,000 population (94). Newborn screening for Krabbe disease in the state of New York yielded a prevalence of infantile Krabbe disease of approximately 1 in 394,000, but it may be higher for later-onset forms (73); the detection of mild or even non-disease-related variants is a complicating issue (74; 73). The early infantile form of Krabbe disease is frequent in the Muslim Arab population in Israel, with a very high prevalence of approximately 6.7 to 10 per 1000 live births (110).
Prevention
In families previously identified through an affected child or by carrier detection, prenatal diagnosis is the only current method for preventing globoid cell leukodystrophy.
Differential diagnosis
Confusing conditions
It is often difficult to distinguish among children with the various forms of inherited degenerative diseases. Recognizing the pattern of abnormalities on brain MRI greatly facilitates the differentiation of Krabbe disease from other disorders (85). MRI imaging abnormalities in Krabbe disease vary according to the specific phenotype (01). Metachromatic leukodystrophy (MLD) shares many features with Krabbe disease, but metachromatic leukodystrophy often begins in the second year of life, and the CT and MRI scans are more likely to demonstrate white matter involvement, especially in the frontal regions (106). Canavan disease, a spongy degeneration of white matter, is associated with macrocephaly, hypotonia early in the course of the disease, and normal CSF protein. Canavan disease has been associated with an accumulation of N-acetylaspartic acid in brain and urine and a deficiency of the enzyme aspartoacylase in fibroblasts (70). In Alexander disease, another cause of macrocephaly in infancy, CT images may show more low-intensity abnormalities in the anterior white matter as well as contrast enhancement in the caudate, fornices, and subependymal white matter (40). Another infantile leukodystrophy, Pelizaeus-Merzbacher disease, differs from Krabbe disease by the prominent nystagmus seen early in infancy and the slow development of spastic quadriplegia (111). GM2 gangliosidosis (Tay-Sachs disease) also begins in infancy, but it is characterized by a cherry-red spot in the retina and the presence of early seizures. Other lysosomal storage diseases that begin in infancy (eg, infantile Gaucher disease, Niemann-Pick disease, Sandhoff disease, and the mucopolysaccharidoses) can be distinguished from Krabbe disease by the presence of systemic signs (ie, organomegaly and dysostosis multiplex) (66).
Diagnostic workup
Enzyme and metabolite assays. With a symptomatic proband, the only specific test that will establish a suspected diagnosis of Krabbe disease is the measurement of galactosylceramidase activity in serum, leukocytes, or cultured fibroblasts. Although most patients have galactosylceramidase activity below 5% of mean normal levels, rare patients with high residual activity have been described (55).
Psychosine quantitation is critical for the correct diagnosis of Krabbe disease in newborn screening (34). Measuring psychosine in dried blood spots helps to differentiate infantile- from later-onset Krabbe disease variants, as well as from GALC variant and pseudodeficiency carriers (34).
Molecular genetic testing. Abnormal results from enzyme assays require follow-up molecular genetic testing of GALC (72).
Biomarkers. A variety of other biomarkers can provide clinically useful information for managing patients with Krabbe disease. However, note that any of the usual biomarkers, such as abnormal neuroimaging, brainstem evoked responses, nerve conduction velocities, and elevated CSF protein, may be normal in up to 25% of patients (25).
Neuroimaging. Early in the course of the disease, when spasticity, fever, and irritability become apparent, CT demonstrates increased density in the brainstem, thalami, caudate nuclei, corona radiata, cerebellar cortex, and periventricular and capsular white matter (83).
Magnetic resonance imaging. The child suspected of having globoid cell leukodystrophy should have an MRI scan to evaluate myelin development. MRI performed during these initial symptoms shows decreased T1 values and normal or slightly decreased T2 values in the abnormal areas demonstrated by CT scan, and large symmetric plaque-like areas on T1- and T2-weighted imaging in the white matter of the centrum semiovale (83; 01). Optic nerve hypertrophy, thought to be due to extensive gliosis, has been noted in MRI studies of a child with early infantile-onset Krabbe disease (88). As the disease progresses, brain atrophy, decreased attenuation in white matter, and symmetric punctate high-density areas in the corona radiata are noted on CT scan, whereas high attenuation on T2-weighted images and low attenuation on T1-weighted images are present in white matter on MRI scans (83; 01; 98).
Remarkable brain MRI features include enlargement and, sometimes, enhancement of the optic nerves and chiasm, and variably other cranial nerves and the cauda equina (32; 43). Selective involvement of the corticospinal tracts is often also present in the late-onset form (87; 16).
Rarely, brain MRI can be normal, even in the early-onset form (47). Subsequently, other studies performed in infantile-onset Krabbe disease have demonstrated a decreased signal on T2-weighted images from the thalamus and basal ganglia (particularly the globus pallidus) with increased T2-weighted signal in centrum semiovale, corpus callosum, internal capsule, midbrain, and pons (98). All parameters of diffusion-weighted imaging are abnormal, particularly radial diffusivity reflecting the white matter abnormality of Krabbe disease (76). Variable atrophy of the midbrain viewed sagittally may be rather useful and correlates with clinical severity and other neuroimaging aspects (114).
Pattern-recognition approach for MRI. A pattern-recognition approach has been described for MRI in Krabbe disease (56); this approach categorizes MRI results into four patterns: A1, A2, B1, and B2.
Pattern A1. Pattern A1 is present in all early-infantile cases.
|
• Cerebral white matter changes, beginning in the central region. | |
|
• Cerebellar white matter changes and signal changes of the dentate nucleus. | |
|
• Involvement of the corpus callosum and the pyramidal tract. | |
|
• In the early-infantile form, signal change in the dentate nucleus (hyperintense on T2-weighted images) may be an early sign but may not persist. | |
|
• In the advanced stage: global atrophy, diffusely affected white matter, and cystic degeneration of the pyramidal tract. |
Pattern A2. Pattern A2 is seen in children with a late-infantile onset and is very similar to pattern A1, except the dentate nucleus is not affected.
In children affected with this pattern, the cerebellar white matter is affected relatively late during the disease course and demyelination starts in the central region and spreads outward.
Pattern B1. Pattern B1 is seen in all later onset patients (ie, all patients with first symptoms after the first year of life up to age ten years).
Occasional patients with either late-infantile onset or onset beyond 10 years may also show this pattern.
|
• White matter signal changes, primarily in the periventricular parieto-occipital region. | |
|
• The corpus callosum (body and splenium) is affected. | |
|
• Pyramidal tract abnormalities (as in patterns A1 and A2). | |
|
• The cerebellum is not affected. |
Pattern B2. Pattern B2 is seen in an adult patient with a late onset (ie, first symptoms at age 60 years).
|
• Visible abnormalities largely restricted to the pyramidal tract. | |
|
• Some focal white matter abnormalities. |
The "Loes score" for MRI. Assessment of an intermediate outcome of hematopoietic stem cell transplantation can be done with the brain MRI "Loes score," a MRI severity scoring system developed originally for use in patients with adrenoleukodystrophy (62; 77; 56).
Development of MRI abnormalities (Loes score) during disease course in early-infantile Krabbe disease
(Source: Krieg SI, Krägeloh-Mann I, Groeschel S, et al. Natural history of Krabbe disease: a nationwide study in Germany using clinical and MRI data. Orphanet J Rare Dis 2020;15[1]:243. Creative Commons Attribution 4.0 Internat...
Cerebrospinal fluid. CSF in patients with early and late infantile forms of Krabbe disease shows elevated protein (frequently 75 to 500 mg/dL) with normal cell counts (103). CSF glycolipids demonstrate reduced galactosylceramide and trace amounts of lactosylceramide but no evidence of psychosine (48).
Neurophysiological studies. Electroencephalograms are usually normal during the early stages, but later, the background slows and becomes irregular with frequent multifocal spike waves (45).
Nerve conduction velocities are slowed in the early infantile form, consistent with a demyelinating disorder (89), but may be normal in adult-onset patients. Electromyograms frequently show evidence of axonal injury, with a reduced number of high-amplitude motor unit action potentials (MUAPs) and occasional fibrillations.
Electron microscopy of eccrine sweat glands. Ultrastructural data suggest that Krabbe disease may be diagnosed based on electron microscopic inclusions in eccrine sweat glands (33); the inclusions appear similar to those seen in Schwann cells, consisting of needle-like and cleft-type inclusions (33).
Management
Benzodiazepines or low-dose morphine have been used for the symptomatic treatment of severe irritability (91). Since this was suggested, though, there has been a shift away from the use of either medication for such indications.
Hematopoietic stem cell transplantation (HSCT)
Mouse model. Bone marrow transplantation (BMT) has been used in a murine model of Krabbe disease, the twitcher mouse. The lifespan of the twitcher mouse was prolonged, with remyelination noted in peripheral nerves (108). Donor-derived macrophages could be demonstrated with extensive remyelination in the CNS of mice receiving bone marrow transplantation, and significant increases in galactocerebroside beta-galactosidase levels were noted along with a reduction of galactosylceramide and psychosine in several organs (44; 41).
Human studies. Hematopoietic stem cell transplantation has been performed in several patients with Krabbe disease with some success. In a study of five patients with Krabbe disease (four juvenile- and one infantile-onset) who received hematopoietic stem cell transplantation (HSCT), all the treated patients had significant improvements in their neurologic symptoms (57). The four late-onset cases demonstrated improvement in MRI findings and reversal of protein elevation in CSF.
Hematopoietic stem cell transplantation in infants before disease onset using umbilical cord blood greatly augments survival, mitigates cognitive decline, and produces a somewhat less severe motor phenotype (27). Although nerve conduction improves in the transplanted patients (90), they had substantial residual motor deficit. In the newborn screening performed in New York State over 8 years, five infants were diagnosed with early infantile Krabbe disease (101): three died--two from transplantation-related complications and one from untreated disease. Two children who received hematopoietic transplantation have moderate to severe developmental delays.
Newborn screening and transplantation in the days after birth remain controversial. A group from Duke University suggests that transplantation before age 30 days provides a significantly better mobility outcome, with 90% able to walk independently or with an assist device and 80% developing normal speech, although 60% required special resources in school (02). However, the New York state experience was much less positive (101). In a study of 18 patients in Pittsburgh, 15 patients were identified prenatally because of family history, and only three infants were identified by state-mandated newborn screening (107). Hematopoietic stem cell transplantation only delayed disease progression and was not curative.
Most patients treated early probably had prenatal-onset and substantial motor impairments with spasticity because of corticospinal tract pathology. In addition, many survivors, particularly if transplanted after 30 days of age, had variable degrees of feeding, vision, hearing, language, and cognitive impairment.
Bone marrow transplantation can be useful for late-onset Krabbe disease (61).
Gene therapy in animal models. Gene therapy using adeno-associated virus has been used in the animal model (78). Early intervention of combined hematopoietic stem cell transplantation and lentiviral-mediated gene transfer to newborn twitcher pups before postnatal day 2 prolonged survival, but it did not prevent ultimate axonal degeneration (31). A combination of more than one form of therapy might be needed (79). In a dog model of the disease, a combination of intravenous and intracerebroventricular injections of AAVrh10 targeted both the peripheral and the central nervous system (12). This approach showed a clear dose response and resulted in delayed onset of clinical signs, extended lifespan, correction of biochemical defects, and attenuation of neuropathology.
Special considerations
Pregnancy
The disease appears to begin in utero because globoid cells and galactosylsphingosine accumulation have been reported in the fetus (26; 51). Prenatal diagnosis is available using direct chorionic villus sampling at 8 to 9 weeks, or later in pregnancy using cultured amniotic fluid cells (103).
Media
References
- 01
- Abdelhalim AN, Alberico RA, Barczykowski AL, Duffner PK. Patterns of magnetic resonance imaging abnormalities in symptomatic patients with Krabbe disease correspond to phenotype. Pediatric neurology 2014;50:127-34. PMID 24262341
- 02
- Allewelt H, Taskindoust M, Troy J, et al. Long-term functional outcomes after hematopoietic stem cell transplant for early infantile Krabbe disease. Biol Blood Marrow Transplant 2018;24(11):2233-8. PMID 29933067
- 03
- Anzil AP, Blinzinger K, Mehraein P, Dorn G, Neuhauser G. Cytoplasmic inclusions in a child affected with Krabbe's disease (globoid leucodystrophy) and in the rabbit injected with galactocerebrosides. J Neuropathol Exp Neurol 1972;31:370-88. PMID 4337275
- 04
- Arvidsson J, Hagberg B, Mansson JE, Svennerholm L. Late onset globoid cell leukodystrophy (Krabbe's disease): Swedish case with 15 years of follow-up. Acta Paediatr 1995;84:218-21. PMID 7756815
- 05
- Austin JH. Studies in globoid (Krabbe) leukodystrophy, II. Controlled thin layer chromatographic studies of globoid body fractions in seven patients. J Neurochem 1963;10:921-30. PMID 14087696
- 06
- Bascou NA, Marcos MC, Beltran Quintero ML, et al. General anesthesia safety in progressive leukodystrophies: a retrospective study of patients with Krabbe disease and metachromatic leukodystrophy. Paediatr Anaesth 2019;29(10):1053-9. PMID 31359511
- 07
- Beltran-Quintero ML, Bascou NA, Poe MD, et al. Early progression of Krabbe disease in patients with symptom onset between 0 and 5 months. Orphanet J Rare Dis 2019;14(1):46. PMID 30777126
- 08
- Beneke R. Ein Fall hochgradigster ausgedehnter Sklerose des Centralnervensystems. Arch Kinderheilk 1908;47:420-2.
- 09
- Blackwood W, Cumings JN. A histochemical and chemical study of three cases of diffuse cerebral sclerosis. J Neurol Neurosurg Psychiatry 1954;17:33-49. PMID 13131077
- 10
- Briggs LV. History of the psychopathic hospital, Boston, Massachusetts. Boston: Wirght and Potter Printing Co, 1922.
- 11
- Bullard WN, Southard EE. Diffuse gliosis of the cerebral white matter in a child. J Nerv Ment Dis 1906;33:188-93.
- 12
- Bradbury AM, Rafi MA, Bagel J, et al. AAVrh10 gene therapy ameliorates central and peripheral nervous system disease in canine globoid cell leukodystrophy (Krabbe disease). Hum Gene Ther 2018;29(7):785-801. PMID 29316812
- 13
- Calderwood L, Wenger DA, Matern D, Dahmoush H, Watiker V, Lee C. Rare saposin A deficiency: novel variant and psychosine analysis. Mol Genet Metab 2020;129(2):161-4. PMID 31439510
- 14
- Cannizzarro LA, Chen YQ, Rafi MA, Wenger DA. Regional mapping of the human galactocerebrosidase gene (GALC) to 14q31 by in situ hybridization. Cytogenet Cell Genet 1994;66:244-5. PMID 8162701
- 15
- Cantuti Castelvetri L, Givogri MI, Hebert A, et al. The sphingolipid psychosine inhibits fast axonal transport in Krabbe disease by activation of GSK3beta and deregulation of molecular motors. J Neurosci 2013;33(24):10048-56. PMID 23761900
- 16
- Chen J, Zhao Z, Shen H, et al. Genetic origin of patients having spastic paraplegia with or without other neurologic manifestations. BMC Neurol 2022;22(1):180. PMID 35578252
- 17
- Chen YQ, Rafi MA, de Gala G, Wenger DA. Cloning and expression of cDNA encoding a human galactocerebrosidase, the enzyme deficient in globoid cell leukodystrophy. Hum Mol Genet 1993;2:1841-5. PMID 8281145
- 18
- Chen YQ, Wenger DA. Galactocerebroside from human urine: purification and partial characterization. Biochim Biophys Acta 1993;1170:53-61. PMID 8399327
- 19
- Cho KH, Kim MW, Kim SU. Tissue culture model of Krabbe’s disease: psychosine cytotoxicity in rat oligodendrocyte culture. Dev Neurosci 1997;19:321-7. PMID 9215877
- 20
- Claycomb KI, Winokur PN, Johnson KM, et al. Aberrant production of tenascin-C in globoid cell leukodystrophy alters psychosine-induced microglial functions. J Neuropathol Exp Neurol 2014;73(10):964-74. PMID 25192051
- 21
- Collier J, Greenfield JG. The encephalitis periaxialis of Schilder. A clinical and pathological study, with an account of two cases, one of which was diagnosed during life. Brain 1924;47:489-519.
- 22
- Cousyn L, Law-Ye B, Pyatigorskaya N, et al. Brain MRI features and scoring of leukodystrophy in adult-onset Krabbe disease. Neurology 2019;93(7):e647-52. PMID 31337714
- 23
- Debs R, Froissart R, Aubourg P, et al. Krabbe disease in adults: phenotypic and genotypic update from a series of 11 cases and a review. J Inherit Metab Dis 2013;36(5):859-68. PMID 23197103
- 24
- De Gasperi R, Gama Sosa MA, Sartorato E, et al. Molecular basis of late-life globoid-cell leukodystrophy. Hum Mutat 1999;14:256-62. PMID 10477434
- 25
- Duffner PK, Barczykowski A, Jalal K, Yan L, Kay DM, Carter RL. Early infantile krabbe disease: results of the world-wide krabbe registry. Pediatr Neurol 2011;45(3):141-8. PMID 21824559
- 26
- Ellis WG, Schneider EL, McCulloch JR, Suzuki K, Epstein CJ. Fetal globoid cell leukodystrophy (Krabbe disease). Pathological and biochemical examination. Arch Neurol 1973;29:253-7. PMID 4728185
- 27
- Escolar ML, Poe MD, Provenzale JM, et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med 2005;352(20):2069-81. PMID 15901860
- 28
- Fiumara A, Barone R, Arena A, et al. Krabbe leukodystrophy in a selected population with high rate of late onset forms: longer survival linked to c.121G>A (p.Gly41Ser) mutation. Clin Genet 2011;80(5):452-8. PMID 21070211
- 29
- Furuya H, Kukita Y, Nagano S, et al. Adult onset globoid cell leukodystrophy (Krabbe disease): analysis of galactosylceramidase cDNA from four Japanese patients. Hum Genet 1997;100:450-6. PMID 9272171
- 30
- Forbes E, Smith K, Petluru M, Nystrom J, Fridman V. Adult-onset Krabbe disease presenting as isolated sensorimotor demyelinating polyneuropathy: A case report. J Peripher Nerv Syst 2022;27(4):320-4. PMID 36057781
- 31
- Galbiati F, Givogri MI, Cantuti L, et al. Combined hematopoietic and lentiviral gene-transfer therapies in newborn Twitcher mice reveal contemporaneous neurodegeneration and demyelination in Krabbe disease. J Neurosci Res 2009;87(8):1748-59. PMID 19185028
- 32
- Ganesan K, Desai S, Hegde A. Multiple cranial nerve enhancement: uncommon imaging finding in early infantile Krabbe's disease. J Neuroimaging 2010;20(2):195-7. PMID 19021834
- 33
- Goebel HH, Kimura S, Harzer K, Klein H. Ultrastructural pathology of eccrine sweat gland epithelial cells in globoid cell leukodystrophy. J Child Neurol 1993;8:171-4. PMID 8389389
- 34
- Guenzel AJ, Turgeon CT, Nickander KK, et al. The critical role of psychosine in screening, diagnosis, and monitoring of Krabbe disease. Genet Med 2020;22(6):1108-18. PMID 32089546
- 35
- Hagberg B, Kollberg H, Sourander P, Akesson HO. Infantile globoid cell leucodystrophy (Krabbe's disease): a clinical and genetic study of 32 Swedish cases 1953-1967. Neuropadiatrie 1969;1:74-88. PMID 5409293
- 36
- Hallervorden J. Eine speicherungshistiocytose des kindlichen gehirns (Gauchersche Krankheit.). Verh Dtsch Ges Pathol 1948;32:96-107.
- 37
- Harzer K, Hiraiwa M, Paton BC. Saposin (sap) A and C activate the degradation of galalctosylsphingosine. FEBS Lett 2001;508:107-10. PMID 11707278
- 38
- Hawkins-Salsbury JA, Parameswar AR, Jiang X, et al. Psychosine, the cytotoxic sphingolipid that accumulates in Globoid Cell Leukodystrophy, alters membrane architecture. J Lipid Res 2013;54(12):3303-11. PMID 24006512
- 39
- He Z, Pang X, Bai J, et al. A novel GALC gene mutation associated with adult-onset Krabbe disease: a case report. Neurocase 2022;28(3):314-9. PMID 35654103
- 40
- Holland IM, Kendall BE. Computed tomography in Alexander's disease. Neuroradiology 1980;20:103-6. PMID 7422121
- 41
- Hoogerbrugge PM, Suzuki K, Suzuki K, et al. Donor-derived cells in the central nervous system of twitcher mice after bone marrow transplantation. Science 1988;239:1035-8. PMID 3278379
- 42
- Hossain MA, Otomo T, Saito S, et al. Late-onset Krabbe disease is predominant in Japan and its mutant precursor protein undergoes more effective processing than the infantile-onset form. Gene 2014;534(2):144-54. PMID 24252386
- 43
- Hwang M, Zuccoli G, Panigrahy A, Rodriguez D, Poe MD, Escolar ML. Thickening of the cauda equina roots: a common finding in Krabbe disease. Eur Radiol 2016;26(10):3377-82. PMID 27137647
- 44
- Ichioka T, Kishimoto Y, Brennan S, Santos GW, Yeager AM. Hematopoietic cell transplantation in murine globoid cell leukodystrophy (the twitcher mouse): effects on levels of galactosylceramidase, psychosine, and galactocerebrosides. Proc Natl Acad Sci U S A 1987;84:4259-63. PMID 2884662
- 45
- Iinuma K, Onuma A. Electroencephalographic findings in a case of globoid cell leukodystrophy. Tohoku J Exp Med 1975;115:75-9. PMID 1129760
- 46
- Ijichi K, Brown GD, Moore CS, et al. MMP-3 mediates psychosine-induced globoid cell formation: implications for leukodystrophy pathology. Glia 2013;61(5):765-77. PMID 23404611
- 47
- Kamate M, Hattiholi V. Normal neuroimaging in early-onset Krabbe disease. Pediatr Neurol 2011;44(5):374-6. PMID 21481747
- 48
- Kaye EM, Ullman MD, Kolodny EH, Krivit W, Rischert JC. Possible use of CSF glycosphingolipids for the diagnosis and therapeutic monitoring of lysosomal storage diseases. Neurology 1992;42:2290-4. PMID 1461381
- 49
- Kehrer C, Blumenstock G, Raabe C, Krägeloh-Mann I. Development and reliability of a classification system for gross motor function in children with metachromatic leucodystrophy. Dev Med Child Neurol 2011;53(2):156-60. PMID 21087233
- 50
- Kleijer WJ, Keulemans JL, van der Kraan M, et al. Prevalent mutations in the GALC gene of patients with Krabbe disease of Dutch and other European origin. J Inherit Metab Dis 1997;20:587-94. PMID 9266397
- 51
- Kobayashi T, Goto I, Yamanaka T, et al. Infantile and fetal globoid cell leukodystrophy: analysis of galactosylceramide and galactosylsphingosine. Ann Neurol 1988;24:517-22. PMID 3239954
- 52
- Kobayashi T, Shinnoh N, Goto I, Kuroiwa Y. Hydrolysis of galactosylceramide is catalyzed by two genetically distinct acid beta-galactosidases. J Biol Chem 1985;260:14982-7. PMID 3934152
- 53
- Kondziella D. Thirty neurological eponyms associated with the Nazi era. Eur Neurol 2009;62(1):56-64. PMID 19407456
- 54
- Krabbe K. New familial, infantile form of diffuse brain-sclerosis. Brain 1916;39:74-114.
- 55
- Krageloh-Mann I, Harzer K, Rostasy K, et al. Late onset Krabbe disease due to the new GALC p.Ala543Pro mutation, with intriguingly high residual GALC activity in vitro. Eur J Paediatr Neurol 2017;21(3):522-9. PMID 28109651
- 56
- Krieg S, Krageloh-Mann I,, Groeschel S, et al. Natural history of Krabbe disease—a nationwide study in Germany using clinical and MRI data. Orphanet J Rare Dis 2020;15(1):243. PMID 32912261
- 57
- Krivit W, Shapiro EG, Peters C, et al. Hematopoietic stem-cell transplantation in globoid-cell leukodystrophy. N Engl J Med 1998;338:1119-26. PMID 9545360
- 58
- Kupper H, Kaiser N, Winter N, et al. Enlargement of peripheral nerves in Krabbe disease: the diagnostic value of nerve ultrasound. Muscle Nerve 2020;61(4):E24-7. PMID 32012303
- 59
- Li Y, Xu Y, Benitez BA, et al. Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target. Proc Natl Acad U S A 2019;116(40):20097-103. PMID 31527255
- 60
- Liao P, Gelinas J, Sirrs S. Phenotypic variability of Krabbe disease across the lifespan. Can J Neurol Sci 2014;41(1):5-12. PMID 24384330
- 61
- Lim ZY, Ho AY, Abrahams S, et al. Sustained neurological improvement following reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation for late-onset Krabbe disease. Bone Marrow Transplant 2008;41(9):831-2. PMID 18246117
- 62
- Loes DJ, Hite S, Moser H, et al. Adrenoleukodystrophy: a scoring method for brain MR observations. AJNR Am J Neuroradiol 1994;15(9):1761-6. PMID 7847225
- 63
- Loonen MC, Van Diggelen OP, Janse HC, Kleijer WJ, Arts WF. Late-onset globoid cell leucodystrophy (Krabbe's disease). Clinical and genetic delineation of two forms and their relation to the early-infantile form. Neuropediatrics 1985;16:137-42. PMID 4047347
- 64
- Luzi P, Rafi MA, Wenger DA. Structure and organization of the human galactocerebrosidase (GALC) gene. Genomics 1995;26:407-9. PMID 7601472
- 65
- Luzi P, Rafi MA, Zaka M, et al. Biochemical and pathological evaluation of long-lived mice with globoid cell leukodystrophy after bone marrow transplantation. Mol Genet Metab 2005;86(1-2):150-9. PMID 16169269
- 66
- Lyon G, Adams RD, Kolodny EH. Neurology of hereditary metabolic diseases of children. 2nd edition. New York: McGraw-Hill, 1996.
- 67
- Malandrini A, D'Eramo C, Palmeri S, et al. Peripheral neuropathy in late-onset Krabbe disease: report of three cases. Neurol Sci 2013;34(1):79-83. PMID 22274816
- 68
- Malone MJ. Deficiency in a degradative enzyme system in globoid leukodystrophy. Trans Am Soc Neurochem 1970;1:56.
- 69
- Martin JJ, Ceuterick C, Martin L, et al. Globoid cell leucodystrophy (Krabbe's disease). Peripheral nerve lesion. Acta Neurol Belg 1974;74:356-75. PMID 4377697
- 70
- Matalon R, Michals K, Sebesta D, et al. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan's disease. Am J Med Genet 1988;29:463-71. PMID 3354621
- 71
- Miyatake T, Suzuki K. Globoid cell leukodystrophy: additional deficiency of psychosine galactosidase. Biochem Biophys Res Commun 1972;48:538-43. PMID 5047687
- 72
- Orsini JJ, Escolar ML, Wasserstein MP, et al. Krabbe Disease. In: Adam MP, Everman DB, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle: University of Washington, 2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1238/.
- 73
- Orsini JJ, Kay DM, Saavedra-Matiz CA, et al. Newborn screening for Krabbe disease in New York State: the first eight years' experience. Genet Med 2016;18(3):239-48. PMID 26795590
- 74
- Orsini JJ, Morrissey MA, Slavin LN, et al. Implementation of newborn screening for Krabbe disease: population study and cutoff determination. Clin Biochem 2009;42(9):877-84. PMID 19318021
- 75
- Paiva ARB, Fonseca Neto RE, Afonso CL, Freua F, Nóbrega PR, Kok F. Incidental magnetic resonance imaging findings leading to an unusual diagnosis: Adult onset Krabbe disease. Eur J Neurol 2022;29(6):1859-62. PMID 35212100
- 76
- Poretti A, Meoded A, Bunge M, et al. Novel diffusion tensor imaging findings in Krabbe disease. Eur J Paediatr Neurol 2014;18(2):150-6. PMID 24149099
- 77
- Provenzale JM, Peddi S, Kurtzberg J, Poe MD, Mukundan S, Escolar M. Correlation of neurodevelopmental features and MRI findings in infantile Krabbe's disease. AJR Am J Roentgenol 2009;192(1):59-65. PMID 19098180
- 78
- Rafi MA, Rao HZ, Luzi P, Curtis MT, Wenger DA. Extended normal life after AAVrh10-mediated gene therapy in the mouse model of Krabbe disease. Mol Ther 2012;20(11):2031-42. PMID 22850681
- 79
- Ricca A, Rufo N, Ungari S, et al. Combined gene/cell therapies provide long-term and pervasive rescue of multiple pathological symptoms in a murine model of globoid cell leukodystrophy. Hum Mol Genet 2015;24(12):3372-89. PMID 25749991
- 80
- Sakai N, Fukushima H, Inui K, et al. Human galactocerebrosidase gene: promoter analysis of the 5’-flanking region and structural organization. Biochim Biophys Acta 1998;1395:62-7. PMID 9434153
- 81
- Sakai N, Inui K, Fujii N, et al. Krabbe disease: isolation and characterization of a full-length cDNA for human galactocerebrosidase. Biochem Biophys Res Commun 1994;198:485-91. PMID 8297359
- 82
- Sasaki M, Ebata M, Tanei ZI, et al. An autopsy case report of adult-onset Krabbe disease: Comparison with an infantile-onset case. Pathol Int 2022;72(11):558-65. PMID 36200664
- 83
- Sasaki M, Sakuragawa N, Takashima S, Hanaoka S, Arima M. MRI and CT findings in Krabbe disease. Pediatr Neurol 1991;7:283-8. PMID 1930420
- 84
- Satoh JI, Tokumoto H, Kurohara K, et al. Adult-onset Krabbe disease with homozygous T185C mutation in the galactocerebrosidase gene: unusual MRI findings of corticospinal tract demyelination. Neurology 1997;49:1392-9. PMID 9371928
- 85
- Schiffmann R, van der Knaap MS. Invited article: an MRI-based approach to the diagnosis of white matter disorders. Neurology 2009;72(8):750-9. PMID 19237705
- 86
- Sedel F, Tourbah A, Fontaine B, et al. Leukoencephalopathies associated with inborn errors of metabolism in adults. J Inherit Metab Dis 2008;31(3):295-307. PMID 18344012
- 87
- Sehgal R, Sharma S, Sankhyan N, Kumar A, Gulati S. Selective corticospinal tract involvement in late-onset Krabbe disease. Neurology 2011;77(3):e20. PMID 21768595
- 88
- Shah S, Freeman E, Wolf V, Murthy S, Lotze T. Intracranial optic nerve enlargement in infantile Krabbe disease. Neurology 2012;78(20):e126. PMID 22585439
- 89
- Siddiqi ZA, Sanders DB, Massey JM. Peripheral neuropathy in Krabbe disease: electrodiagnostic findings. Neurology 2006a;67(2):263-7. PMID 16864819
- 90
- Siddiqi ZA, Sanders DB, Massey JM. Peripheral neuropathy in Krabbe disease: effect of hematopoietic stem cell transplantation. Neurology 2006b;67(2):268-72. PMID 16864820
- 91
- Stewart WA, Gordon KE, Camfield PR, Wood EP, Dooley JM. Irritability in Krabbe’s disease: dramatic response to low-dose morphine. Pediatr Neurol 2001;25:344-5. PMID 11704408
- 92
- Suzuki K. Twenty five years of the “psychosine hypothesis”: a personal perspective of its history and present status. Neurochem Res 1998;23:251-9. PMID 9482237
- 93
- Suzuki K, Suzuki Y. Globoid cell leukodystrophy (Krabbe's disease): deficiency of galactocerebroside beta-galactosidase. Proc Nat Acad Sci U S A 1970;66:302-9. PMID 5271165
- 94
- Suzuki K, Suzuki Y. Galactosylceramide lipidosis: globoid-cell leukodystrophy (Krabbe disease). In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic basis of inherited disease. New York: McGraw-Hill, 1989:1699-720.
- 95
- Svennerholm L. Some aspects of biochemical changes in leucodystrophy. In: Folch-Pi J, Bauer H, editors. Brain lipids and lipoproteins and the leucodystrophies. Amsterdam: Elsevier, 1963:104.
- 96
- Taniike M, Mohri I, Eguchi N, et al. An apoptotic depletion of oligodendrocytes in the twitcher, a murine model of globoid cell leukodystrophy. J Neuropathol Exp Neurol 1999;58:644-53. PMID 10374755
- 97
- Tanner AK, Chin EL, Duffner PK, Hegde M. Array CGH improves detection of mutations in the GALC gene associated with Krabbe disease. Orphanet J Rare Dis 2012;7:38. PMID 22704718
- 98
- Thakkar RN, Patel D, Kioutchoukova IP, et al. Leukodystrophy imaging: insights for diagnostic dilemmas. Med Sci (Basel) 2024;12(1):7. PMID 38390857
- 99
- Thomas PK, Halpern JP, King RH, Patrick D. Galactosylceramide lipidosis: novel presentation as a slowly progressive spinocerebellar degeneration. Ann Neurol 1984;16:618-20. PMID 6095734
- 100
- Tokushige S, Sonoo T, Maekawa R, et al. Isolated pyramidal tract impairment in the central nervous system of adult-onset Krabbe disease with novel mutations in the GALC gene. Brain Dev 2013;35(6):579-81. PMID 22959700
- 101
- Wasserstein MP, Andriola M, Arnold G, et al. Clinical outcomes of children with abnormal newborn screening results for Krabbe disease in New York State. Genet Med 2016;18(12):1235-43. PMID 27171547
- 102
- Wenger DA. Studies on galactosyl ceramide and lactosyl ceramide beta-galactosidase. Chem Phys Lipids 1974;13:327-9. PMID 4452215
- 103
- Wenger DA, Rafi MA, Luzi P. Molecular genetics of Krabbe disease (globoid cell leukodystrophy): diagnostic and clinical implications. Hum Mutat 1997;10(4):268-79. PMID 9338580
- 104
- Wenger DA, Sattler M, Markey SP. Deficiency of monogalactosyl diglyceride beta-galactosidase activity in Krabbe's disease. Biochem Biophys Res Commun 1973;53:680-5. PMID 4716994
- 105
- White AB, Givogri MI, Lopez-Rosas A, et al. Psychosine accumulates in membrane microdomains in the brain of krabbe patients, disrupting the raft architecture. J Neurosci 2009;29(19):6068-77. PMID 19439584
- 106
- Wolpert SM, Anderson ML, Kaye EM. Metabolic and degenerative disorders. In: Wolpert SM, Barnes PD, editors. MRI in pediatric neuroradiology. St. Louis: Mosby-Year Book, 1992:121-50.
- 107
- Wright MD, Poe MD, DeRenzo A, Haldal S, Escolar ML. Developmental outcomes of cord blood transplantation for Krabbe disease: a 15-year study. Neurology 2017;89(13):1365-72. PMID 28855403
- 108
- Yeager AM, Brennan S, Tiffany C, Moser HW, Santos GW. Prolonged survival and remyelination after hematopoietic cell transplantation in the twitcher mouse. Science 1984;225:1052-4. PMID 6382609
- 109
- Yunis EJ, Lee RE. The ultrastructure of globoid (Krabbe) leukodystrophy. Lab Invest 1969;21:415-9. PMID 5360530
- 110
- Zayed H. Krabbe disease in the Arab world. J Pediatr Genet 2015;4(1):1-8. PMID 27617109
- 111
- Zeman W, DeMyer WE, Falls HF. Pelizaeus-Merzbacher disease: a study in nosology. J Neuropathol Exp Neurol 1964;23:334-54. PMID 14137679
- 112
- Zhao S, Zhan X, Wang Y, et al. Large-scale study of clinical and biochemical characteristics of Chinese patients diagnosed with Krabbe disease. Clin Genet 2018;93(2):248-54. PMID 28598007
- 113
- Zlotogora J, Chakraborty S, Knowlton RG, Wenger DA. Krabbe disease locus mapped to chromosome 14 by genetic linkage. Am J Hum Genet 1990;47:37-44. PMID 1971996
- 114
- Zuccoli G, Narayanan S, Panigrahy A, Poe MD, Escolar ML. Midbrain morphology reflects extent of brain damage in Krabbe disease. Neuroradiology 2015;57(7):739-45. PMID 25859833
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Author
-
Douglas J Lanska MD MS MSPH
Dr. Lanska of the University of Wisconsin School of Medicine and Public Health and the Medical College of Wisconsin has no relevant financial relationships to disclose.
See Profile
Former Authors
- Edward M Kaye MD
- Martha D Carlson MD PhD
- Raphael Schiffmann MD
Patient Profile
- Age range of presentation
-
- 0 month to 64 years
- Sex preponderance
-
- male=female
- Heredity
-
- heredity typical
- heredity may be a factor
- autosomal recessive
- Population groups selectively affected
-
- none selectively affected
- Occupation groups selectively affected
-
- none selectively affected
ICD & OMIM codes
- ICD-10
-
- Krabbe disease: E75.2
- ICD-11
-
- Krabbe disease: 8A44.4
- OMIM
-
- Krabbe disease: #245200
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Neurogenetic Disorders
Wilson disease
Oct. 23, 2024
-
Neuro-Oncology
Anti-LGI1 encephalitis
Oct. 03, 2024
-
Sleep Disorders
Fatal familial insomnia
Sep. 25, 2024
-
Stroke & Vascular Disorders
White matter abnormalities in the brain
Sep. 12, 2024
-
Neurogenetic Disorders
Hypermethioninemia
Sep. 12, 2024
-
Neurogenetic Disorders
POLG-related mitochondrial disorders
Sep. 12, 2024
-
Neurogenetic Disorders
Multiple acyl-CoA dehydrogenase deficiency
Sep. 12, 2024